EUVIMEDOpdag EUVIMED
Open access

Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies

Daniel Wang iD, Caroline E Porter iD, Bora Lim iD, Amanda Rosewell Shaw iD, Catherine S Robertson, Mae L Woods iD, Ya Xu iD, Greyson G W Biegert iD, Daisuke Morita, Tao Wang iD, Bambi J Grilley, Helen Heslop iD and 2 more

Science Advances · 2023

DOI: 10.1126/sciadv.ade6790 ↗

At a glance

Journal article in Science Advances, 2023. Written by Daniel Wang and 13 co-authors. Institution: Department of Medicine, Baylor College of Medicine, Houston, TX, USA. Major MEDLINE topics: Oncolytic Virotherapy, Oncolytic Viruses, Neoplasms. Cited 26 times so far (Crossref); 42 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, NHLBI NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

We show that a binary oncolytic/helper-dependent adenovirus (CAdVEC) that both lyses tumor cells and locally expresses the proinflammatory cytokine IL-12 and PD-L1 blocking antibody has potent antitumor activity in humanized mouse models. On the basis of these preclinical studies, we treated four patients with a single intratumoral injection of an ultralow dose of CAdVEC (NCT03740256), representing a dose of oncolytic adenovirus more than 100-fold lower than used in previous trials. While CAdVEC caused no significant toxicities, it repolarized the tumor microenvironment with increased infiltration of CD8 T cells. A single administration of CAdVEC was associated with both locoregional and abscopal effects on metastases and, in combination with systemic administration of immune checkpoint antibodies, induced sustained antitumor responses, including one complete and two partial responses. Hence, in both preclinical and clinical studies, CAdVEC is safe and even at extremely low doses is sufficiently potent to induce significant tumor control through oncolysis and immune repolarization.

Subjects

MeSH terms (MEDLINE)

Oncolytic VirotherapyOncolytic VirusesNeoplasmsMiceAnimalsAdenoviridaeCytokinesCell Line, TumorTumor Microenvironment

Substances

Cytokines

Authors and institutions

  • Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX, USA.
  • Duncan Cancer Center-Breast, Baylor College of Medicine, Houston, TX, USA.
  • Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
  • Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
  • Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.

ORCID profiles: Daniel Wang, Caroline E Porter, Bora Lim, Amanda Rosewell Shaw, Mae L Woods, Ya Xu, Greyson G W Biegert, Tao Wang, Helen Heslop, Malcolm K Brenner, Masataka Suzuki

Funding

  • NCI NIH HHS
  • NHLBI NIH HHS

Cite

APA

Wang, D., Porter, C. E., Lim, B., Rosewell Shaw, A., Robertson, C. S., Woods, M. L., Xu, Y., Biegert, G. G. W., Morita, D., Wang, T., Grilley, B. J., Heslop, H., Brenner, M. K., & Suzuki, M. (2023). Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Science Advances. https://doi.org/10.1126/sciadv.ade6790

Vancouver

Wang D, Porter CE, Lim B, Rosewell Shaw A, Robertson CS, Woods ML, et al. Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Science Advances. 2023. doi:10.1126/sciadv.ade6790

BibTeX
@article{Wang2023,
  author = {Wang, Daniel and Porter, Caroline E and Lim, Bora and Rosewell Shaw, Amanda and Robertson, Catherine S and Woods, Mae L and Xu, Ya and Biegert, Greyson G W and Morita, Daisuke and Wang, Tao and Grilley, Bambi J and Heslop, Helen and Brenner, Malcolm K and Suzuki, Masataka},
  title = {Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies},
  journal = {Science Advances},
  year = {2023},
  doi = {10.1126/sciadv.ade6790}
}
Start for free →